Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M173,886Revenue $M44,033Net Margin (%)12.9Z-Score3.1
Enterprise Value $M187,090EPS $1.5Operating Margin %14.4F-Score4
P/E(ttm))40.0Cash Flow Per Share $6.3Pre-tax Margin (%)15.5Higher ROA y-yN
Price/Book3.610-y EBITDA Growth Rate %3.1Quick Ratio1.6Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %-6.3Current Ratio1.8Lower Leverage y-yN
Price/Cash Flow7.1y-y EBITDA Growth Rate %-9.2ROA % (ttm)5.3Higher Current Ratio y-yN
Dividend Yield %2.9Insider Buy (3m)0ROE % (ttm)11.6Less Shares Outstanding y-yY
Payout Ratio %92.0Shares Outstanding M2,922ROI % (ttm)6.0Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKJoel Greenblatt 2014-06-30 Add0.09%$54.83 - $59.62
($57.16)
$ 60.576%Add 3456.04%126,844
MRKGeorge Soros 2014-06-30 Buy 0.04%$54.83 - $59.62
($57.16)
$ 60.576%New holding, 86800 sh.86,800
MRKVanguard Health Care Fund 2014-06-30 Reduce-0.28%$54.83 - $59.62
($57.16)
$ 60.576%Reduce -4.85%33,889,948
MRKDodge & Cox 2014-06-30 Reduce-0.23%$54.83 - $59.62
($57.16)
$ 60.576%Reduce -10.01%35,960,137
MRKJean-Marie Eveillard 2014-06-30 Reduce-0.07%$54.83 - $59.62
($57.16)
$ 60.576%Reduce -21.54%1,755,082
MRKDavid Dreman 2014-06-30 Sold Out -0.02%$54.83 - $59.62
($57.16)
$ 60.576%Sold Out0
MRKJean-Marie Eveillard 2014-03-31 Add0.34%$49.49 - $57.47
($54.09)
$ 60.5712%Add 15820.6%2,236,839
MRKDavid Dreman 2014-03-31 Buy 0.02%$49.49 - $57.47
($54.09)
$ 60.5712%New holding, 4431 sh.4,431
MRKJoel Greenblatt 2014-03-31 Buy $49.49 - $57.47
($54.09)
$ 60.5712%New holding, 3567 sh.3,567
MRKJames Barrow 2014-03-31 Reduce-0.48%$49.49 - $57.47
($54.09)
$ 60.5712%Reduce -22.72%22,739,030
MRKDodge & Cox 2014-03-31 Reduce-0.45%$49.49 - $57.47
($54.09)
$ 60.5712%Reduce -18.11%39,959,196
MRKVanguard Health Care Fund 2014-03-31 Reduce-0.15%$49.49 - $57.47
($54)
$ 60.5712%Reduce -2.58%35,616,848
MRKGeorge Soros 2014-03-31 Sold Out -0.06%$49.49 - $57.47
($54.09)
$ 60.5712%Sold Out0
MRKJohn Hussman 2014-03-31 Sold Out -0.01%$49.49 - $57.47
($54)
$ 60.5712%Sold Out0
MRKGeorge Soros 2013-12-31 Buy 0.06%$45.09 - $50.18
($47.86)
$ 60.5727%New holding, 150000 sh.150,000
MRKRuane Cunniff 2013-12-31 Buy $45.09 - $50.18
($47.86)
$ 60.5727%New holding, 4075 sh.4,075
MRKJean-Marie Eveillard 2013-12-31 Reduce-0.16%$45.09 - $50.18
($47.86)
$ 60.5727%Reduce -98.76%14,050
MRKLeon Cooperman 2013-12-31 Sold Out -0.15%$45.09 - $50.18
($47.86)
$ 60.5727%Sold Out0
MRKCharles Brandes 2013-12-31 Reduce-0.14%$45.09 - $50.18
($47.86)
$ 60.5727%Reduce -8.39%2,476,201
MRKJean-Marie Eveillard 2013-09-30 Reduce-0.16%$46.55 - $48.58
($47.88)
$ 60.5726%Reduce -49.6%1,134,041
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
MRK George Soros 2014-06-3086,80000.04New Buy
MRK Joel Greenblatt 2014-06-30126,84400.09+3456.04%
MRK Ruane Cunniff 2014-06-304,60900+4.54%
MRK James Barrow 2014-06-3022,793,2070.781.8+0.24%
MRK Mario Gabelli 2014-06-30160,3160.010.05
MRK Prem Watsa 2014-06-3012,00000.05
MRK Charles Brandes 2014-06-302,434,5310.081.7-0.68%
MRK Vanguard Health Care Fund 2014-06-3033,889,9481.165.2-4.85%
MRK Dodge & Cox 2014-06-3035,960,1371.232-10.01%
MRK Jean-Marie Eveillard 2014-06-301,755,0820.060.25-21.54%
MRK David Dreman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FRAZIER KENNETH CChairman, President & CEO 2014-09-10Sell9,814$60.480.02view
Schechter Adam HEVP & Pres-Global Human Health 2014-08-25Sell22,000$59.71.32view
FRAZIER KENNETH CChairman, President & CEO 2014-08-11Sell10,058$576.12view
AMBROSE ADELE DSr.V-P & Chief Comuns Officer 2014-08-04Sell28,669$56.646.8view
FRAZIER KENNETH CChairman, President & CEO 2014-07-10Sell9,987$58.034.24view
GRADDICK WEIR MIRIAN MExe V-P, HR 2014-07-07Sell180,047$59.162.25view
GRADDICK WEIR MIRIAN MExe V-P, HR 2014-07-07Sell180,047$59.162.25view
Deese Willie AExe V-P & Pres. MMD 2014-06-27Sell72,290$58.263.83view
FRAZIER KENNETH CChairman, President & CEO 2014-06-10Sell9,985$58.064.19view
Schechter Adam HEVP & Pres-Global Human Health 2014-05-14Sell10,527$55.918.19view

Press Releases about MRK :

Quarterly/Annual Reports about MRK:

    News about MRK:

    Articles On GuruFocus.com
    The Dogs of the Dow Lost Some Steam In The August Heat, But Maintained Their Lead Sep 16 2014 
    The Dogs of the Dow Lost Some Steam In The August Heat, But Maintained Their Lead Sep 16 2014 
    I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
    Higher Yielding Stocks With A Cheap EV/EBITDA Ratio And Low Debt Figures Aug 28 2014 
    Legendary Investor Irving Kahn's Top Five Stocks Aug 08 2014 
    UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
    U.S. Markets Regain Losses from Last Week Jul 14 2014 
    Abner Herrman Is Increasing Position in the Pharmaceutical Sector Jul 11 2014 
    U.S. Equity Markets Continue to Hit New Highs Jun 15 2014 
    Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 


    More From Other Websites
    Is Merck KGaA on Track with its "Fit for 2018" Program? Sep 19 2014
    Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus... Sep 19 2014
    Merck KGaA Teams Up with Sutro for ADCs Targeting Cancer Sep 18 2014
    Bayer Deal for Zoetis in Sight After Unit Sale: Real M&A Sep 18 2014
    Merck Enters into Licensing Agreement with Sun Pharma Sep 18 2014
    French cancer immunotherapy specialist OSE Pharma prepares IPO Sep 18 2014
    Credit Suisse Gold Standard Yield Stocks May Be the Safest to Own Now Sep 18 2014
    Bayer to float plastics business and focus on life sciences Sep 18 2014
    Merck KGaA seeks partner for immuno-oncology drug by year-end Sep 18 2014
    Merck KGaA seeks partner for immuno-oncology drug by year-end Sep 18 2014
    Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab Sep 17 2014
    Sun Pharma licenses Merck psoriasis drug for $80M Sep 17 2014
    Sun Pharma licenses Merck psoriasis drug for $80M Sep 17 2014
    Merck licenses experimental psoriasis drug to Sun Pharma Sep 17 2014
    Merck licenses experimental psoriasis drug to Sun Pharma Sep 17 2014
    Merck licenses experimental psoriasis drug to India's Sun Pharma Sep 17 2014
    Dow Jones (DJIA) Today: E I Du Pont De Nemours & Company (DD) Leads The Day Higher, Merck (MRK) Lags Sep 17 2014
    MSD Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational... Sep 17 2014
    Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational... Sep 17 2014
    Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab Sep 17 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK